← Leaderboards
Natarajan Ranganathan
Kibow Biotech, Inc.
$1,926,056
Attributed
$1,926,056
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,926,056 · 2
By mechanism
R44$1,926,056 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionLaboratory RatBiotherapeutic AgentDietary SupplementsDisease /Disorder ModelDogsDrug Screening /EvaluationEscherichia ColiGastrointestinal Drug AbsorptionGenetic ManipulationHorsesKidney DisorderKidney Disorder ChemotherapyKidney FunctionMicroorganism CultureMicroorganism GrowthNonhuman Therapy EvaluationNutrition Related TagTechnology /Technique DevelopmentUremiasBacteriaYeastsCatsComputer Simulation
Grant awards (6)
A dietary supplement for augmenting kidney function$499,111
R44 · FY2004 · DK
A dietary supplement for augmenting kidney function$476,945
R44 · FY2003 · DK
SORBENTS+ENGINEERED BACTERIA AS GUT-BASED UREMIA THERAPY$313,327
R44 · FY2002 · DK
A dietary supplement for augmenting kidney function$100,000
R44 · FY2002 · DK
SORBENTS+ENGINEERED BACTERIA AS GUT-BASED UREMIA THERAPY$436,673
R44 · FY2001 · DK
SORBENTS+ENGINEERED BACTERIA AS GUT-BASED UREMIA THERAPY$100,000
R44 · FY2000 · DK